Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: The US Food and Drug Administration
recently announced the premature discontinuation of ADAPT due to an apparent
increase in adverse cardiovascular events associated with naproxen.1 Because previous reports have shown naproxen to have
a cardioprotective effect, this finding was unexpected and has caused a considerable
amount of confusion among practitioners and the public.2
Lehmann DF. Arthritis Medications and Cardiovascular Events. JAMA. 2005;293(16):1975-1977. doi:10.1001/jama.293.16.1976-a